Analysis of clinical characteristics and risk factors of lupus nephritis combined with neuropsychiatric systemic lupus erythematosus in children

  • Han Kaiyang ,
  • Feng Tongtong ,
  • Bao Ying
Expand
  • 1. Graduate Studies Office,Xi'an Medical University,Xi'an 710021,China
    2. Department of Nephrology,Xi'an Children's Hospital,Xi'an 710003,China
Bao Ying,Email: baoybj@126.com

Received date: 2024-06-15

  Online published: 2024-09-24

Abstract

Objective To explore the clinical characteristics of children with lupus nephritis (LN) complicated with neuropsychiatric systemic lupus erythematosus (NPSLE), and to analyze the risk factors of LN complicated with NPSLE.Methods A total of 119 children with LN who were admitted to the Department of Nephrology, Xi'an Children's Hospital from May 2017 to January 2024 were enrolled. They were divided into NPSLE group (n=26) and non-NPSLE group (n=93) according to the presence or absence of NPSLE. Clinical data were compared between the two groups, and the clinical characteristics and risk factors of LN children with NPSLE were analyzed.Results The incidence of NPSLE in children with LN was 21.8%, with male-to-female ratio of 1∶5.5, and an average age of 10 years and 6 months. The most common neurological manifestations were psychiatric abnormalities, erythema discoideum in general, and abnormalities of cranial MRI on imaging. There were significant differences in antinuclear antibody positivity, anti-ds-DNA antibody positivity, anti-Smith (anti-SM) antibody positivity, reduction of white blood cells, red blood cells and platelets, performance of only anemia, high erythrocyte sedimentation rate (>15 mm/h), hypoproteinemia, positive Coombs test, hematuria and massive proteinuria between the two groups (P<0.05). Binary logistic regression analysis showed that hematuria, massive proteinuria and positive anti-SM antibody were independent risk factors for NPSLE in children with LN. Conclusion A variety of factors can influence whether LN is comorbid with NPSLE, with children with LN who have haematuria, large amounts of proteinuria, and positive anti-SM antibodies being prone to comorbid neuropsychiatric changes.

Cite this article

Han Kaiyang , Feng Tongtong , Bao Ying . Analysis of clinical characteristics and risk factors of lupus nephritis combined with neuropsychiatric systemic lupus erythematosus in children[J]. Clinical Focus, 2024 , 39(9) : 812 -815 . DOI: 10.3969/j.issn.1004-583X.2024.09.008

References

[1] 刘平丹. 血浆细胞外囊泡、Serpinc1在系统性红斑狼疮中的表达及其作用[D]. 南充: 川北医学院, 2023.
[2] Hou Y, Wang L, Luo C, et al. Clinical characteristics of early-onset paediatric systemic lupus erythematosus in a single centrein China[J]. Rheumatology(Oxford), 2023, 62(10):3373-3381.
[3] 端爱萍, 高少辉, 鲍浩. 溶酶体在肾小球疾病中的研究进展[J]. 肾脏病与透析肾移植杂志, 2024, 33(1):54-58.
[4] 罗玉立, 杨一帆, 罗家昂, 等. 神经精神狼疮血脑屏障损伤机制的研究进展[J]. 医学综述, 2020, 26(19):3758-3762+3768.
[5] 程程, 文思佳, 林知朗, 等. 儿童狼疮性肾炎的疗效及预后分析[J]. 中华儿科杂志, 2021, 59(9):730-736.
[6] Nie S, He W, Huang T, et al. The spectrum ofbiopsy-proven glomerular diseases among children in china: A national, cross-sectional survey[J]. Clin J Am Soc Nephrol, 2018, 13(7): 1047-1054.
[7] 赵娟, 屈嘉豪, 刘力源, 等. 神经精神狼疮109例临床特点及生存分析[J]. 中华风湿病学杂志, 2021, 25(11):733-738.
[8] Aringer M. EULAR/ACR classification criteria for SLE[J]. Semin Arthritis Rheum, 2019, 49(3S):S14-S17.
[9] Amorim JC, Frittoli RB, Pereira D, et al. Epidemiology, characterization, and diagnosis of neuropsychiatric events in systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2019, 15(4):407-416.
[10] Waldman M, Madaio MP. Pathigenic autoatibodies in lupus nephritis[J]. Lups, 2005, 14(1):19-24.
[11] 石丹英, 儿童神经精神狼疮临床特征及危险因素分析[D]. 南宁: 广西医科大学, 2020.
[12] Ahn GY, Kim D, Won S, et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: A prospective, single-center study[J]. Lupus, 2018, 27(8) :1338-1347.
[13] 郭旭娟, 刘秀梅. 系统性红斑狼疮脑病危险因素的meta分析[J]. 中国免疫学杂志, 2020, 36(4):484-490.
[14] 孟庆防. 系统性红斑狼疮并狼疮脑病临床特点分析[J]. 中国实用神经疾病杂志, 2017, 20(6):86-88.
[15] Brandusa F, Ellie A, Jiandong S, et al. Peripheral neu-ropathy in patients with systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2012, 41(2):203-211.
[16] Luyendijk J, Steens SC, Ouwendijk WJ, et al. Neuropsychiatric systemic lupus erythematosus:Lessons learned from magnetic resonance imaging[J]. Arthritis Rheum, 2014, 63(3):722-732.
[17] Dale RC, Fabienne B, Duffy LV, et al. Utility andsafety of rituximab in pediatric autoimmune and inflammatory CNS disease[J]. Neurology, 2014, 83(2):142-150.
[18] 凌磊, 皮肖冰, 余旸弢, 等. 系统性红斑狼疮患者血清干扰素-α的水平变化及其临床意义[J]. 实用医学杂志, 2016, 32(1):106-108.
[19] Furie R, Merrill JT, Werth VP, et al. Anifrolumab,an antiinterferon-α receptor monoclonal antibody,in moderate-to-severe systemic lupus erythematosus[J]. Arthritis Rheumatol, 2017, 69(2):376-386.
[20] Huang MW, Stock AD, Mike EV, et al. Anti-IFNAR treatment does not reverse neuropsychiatric disease in MRL//lpr lupus mice[J]. Lupus, 2019, 28(13):1510-1523.
Outlines

/